Find Gastroenterology Clinical Drug Pipeline Developments & Deals

Lead Product(s): Glutamine

Therapeutic Area: Gastroenterology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 29, 2020

Details:

A marginal but decreased size in some of the diverticula compared to the baseline. Indications of Healing and Normalization of Bowel Movements Observed in the Initial Patient.

Lead Product(s): Brazikumab

Therapeutic Area: Gastroenterology

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: AstraZeneca

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Divestment January 27, 2020

Details:

AstraZeneca will acquire brazikumab, in Phase 2b/3 development for Crohn's Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights.

Lead Product(s): Fosnetupitant Chloride,Palonosetron

Therapeutic Area: Gastroenterology

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Helsinn Group

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 27, 2020

Details:

Berlin-Chemie AG has been granted exclusive rights to import, distribute, promote, market and sell AKYNZEO® and ONICIT® in Russia and CIS region to manage chemotherapy-induced nausea and vomiting.

Lead Product(s): Brilacidin

Therapeutic Area: Gastroenterology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 24, 2020

Details:

Brilacidin utilizing new delayed release technology for targeted delivery directly to colon.

Lead Product(s): ALPN-101

Therapeutic Area: Gastroenterology

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 24, 2020

Details:

The new data demonstrate the unique potency of ALPN-101 as measured by in vitro assays involving PBMC’s from patients with Crohn’s Disease or Ulcerative colitis and in vivo mouse models of colitis.

Lead Product(s): Metoclopramide

Therapeutic Area: Gastroenterology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Eversana

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 23, 2020

Details:

Under the terms of the agreement, Evoke retains Gimoti NDA rights as well as all legal, regulatory and production obligations, while EVERSANA will sell and supply Gimoti in the United States.

Lead Product(s): Linaclotide

Therapeutic Area: Gastroenterology

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Teva Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement January 23, 2020

Details:

Pursuant to the terms of the settlement, Ironwood and Allergan will grant Teva a license to market its 145 mcg and 290 mcg generic version of LINZESS in U.S.

Lead Product(s): GB004

Therapeutic Area: Gastroenterology

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 23, 2020

Details:

Gossamer bio is conducting a Phase 1 multiple ascending dose study of GB004 in healthy volunteers with Gut Biopsies.

Lead Product(s): Galacto-oligosaccharide

Therapeutic Area: Gastroenterology

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Qualigen